ACCELERON PHARMA INC Insider Trading for January 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC for January 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 52.99 | 8,185 | 433,723 | 8,185 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 1,377 | 0 | 2,939 | 1.6 K to 2.9 K (+88.16 %) |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | A | 52.99 | 8,185 | 433,723 | 8,185 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Grant | A | 0.00 | 1,377 | 0 | 32,877 | 31.5 K to 32.9 K (+4.37 %) |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | A | 52.99 | 8,185 | 433,723 | 8,185 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Grant | A | 0.00 | 1,377 | 0 | 4,422 | 3 K to 4.4 K (+45.22 %) |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Option Exercise | A | 52.99 | 8,185 | 433,723 | 8,185 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Grant | A | 0.00 | 1,377 | 0 | 5,127 | 3.8 K to 5.1 K (+36.72 %) |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | A | 52.99 | 8,185 | 433,723 | 8,185 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Grant | A | 0.00 | 1,377 | 0 | 5,127 | 3.8 K to 5.1 K (+36.72 %) |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 52.99 | 8,185 | 433,723 | 8,185 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Grant | A | 0.00 | 1,377 | 0 | 5,127 | 3.8 K to 5.1 K (+36.72 %) |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Option Exercise | A | 52.99 | 24,334 | 1,289,459 | 24,334 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Grant | A | 0.00 | 6,369 | 0 | 21,161 | 14.8 K to 21.2 K (+43.06 %) |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Option Exercise | A | 52.99 | 24,334 | 1,289,459 | 24,334 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Grant | A | 0.00 | 6,369 | 0 | 15,939 | 9.6 K to 15.9 K (+66.55 %) |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 52.99 | 24,334 | 1,289,459 | 24,334 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Grant | A | 0.00 | 6,369 | 0 | 11,216 | 4.8 K to 11.2 K (+131.40 %) |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Option Exercise | A | 52.99 | 84,720 | 4,489,313 | 84,720 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Grant | A | 0.00 | 22,173 | 0 | 89,324 | 67.2 K to 89.3 K (+33.02 %) |
| Jan 09 2020 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | M | 3.88 | 18,750 | 72,750 | 0 | |
| Jan 09 2020 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Buy | M | 3.88 | 18,750 | 72,750 | 31,500 | 12.8 K to 31.5 K (+147.06 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 51.23 | 875 | 44,826 | 14,792 | 15.7 K to 14.8 K (-5.58 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 52.83 | 434 | 22,928 | 15,667 | 16.1 K to 15.7 K (-2.70 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Sell | S | 51.27 | 11 | 564 | 9,570 | 9.6 K to 9.6 K (-0.11 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Sell | S | 51.37 | 469 | 24,093 | 9,581 | 10.1 K to 9.6 K (-4.67 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Sell | S | 52.52 | 4,242 | 222,790 | 53,316 | 57.6 K to 53.3 K (-7.37 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Sell | S | 52.51 | 1,600 | 84,016 | 57,558 | 59.2 K to 57.6 K (-2.70 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 52.52 | 1,566 | 82,246 | 4,847 | 6.4 K to 4.8 K (-24.42 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 52.49 | 2,300 | 120,727 | 6,413 | 8.7 K to 6.4 K (-26.40 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 52.51 | 1,713 | 89,950 | 8,713 | 10.4 K to 8.7 K (-16.43 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 51.24 | 3,634 | 186,206 | 67,151 | 70.8 K to 67.2 K (-5.13 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 51.26 | 98 | 5,023 | 70,785 | 70.9 K to 70.8 K (-0.14 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Backstrom Jay T. | EVP, Research and D ... | Option Exercise | A | 52.61 | 94,865 | 4,990,848 | 94,865 | |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Backstrom Jay T. | EVP, Research and D ... | Grant | A | 0.00 | 17,107 | 0 | 17,107 | 0 to 17.1 K |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Malik Kemal | Director | Option Exercise | A | 52.61 | 17,567 | 924,200 | 17,567 | |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 51.23 | 875 | 44,826 | 14,792 | 15.7 K to 14.8 K (-5.58 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | VP, General Counsel ... | Sell | S | 52.83 | 434 | 22,928 | 15,667 | 16.1 K to 15.7 K (-2.70 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Sell | S | 51.27 | 11 | 564 | 9,570 | 9.6 K to 9.6 K (-0.11 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Sell | S | 51.37 | 469 | 24,093 | 9,581 | 10.1 K to 9.6 K (-4.67 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Sell | S | 52.52 | 4,242 | 222,790 | 53,316 | 57.6 K to 53.3 K (-7.37 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Sell | S | 52.51 | 1,600 | 84,016 | 57,558 | 59.2 K to 57.6 K (-2.70 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 52.52 | 1,566 | 82,246 | 4,847 | 6.4 K to 4.8 K (-24.42 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 52.49 | 2,300 | 120,727 | 6,413 | 8.7 K to 6.4 K (-26.40 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 52.51 | 1,713 | 89,950 | 8,713 | 10.4 K to 8.7 K (-16.43 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 51.24 | 3,634 | 186,206 | 67,151 | 70.8 K to 67.2 K (-5.13 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 51.26 | 98 | 5,023 | 70,785 | 70.9 K to 70.8 K (-0.14 %) |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Backstrom Jay T. | EVP, Research and D ... | Option Exercise | A | 52.61 | 94,865 | 4,990,848 | 94,865 | |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Backstrom Jay T. | EVP, Research and D ... | Grant | A | 0.00 | 17,107 | 0 | 17,107 | 0 to 17.1 K |
| Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Malik Kemal | Director | Option Exercise | A | 52.61 | 17,567 | 924,200 | 17,567 |